{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Murphy C"],"funding":["NCI NIH HHS","Pacific Northwest Prostate Cancer SPORE"],"pagination":["1285-92"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4988926"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["76(14)"],"pubmed_abstract":["Background
Pathologic variables that characterize response of prostate carcinoma to current neoadjuvant therapy have not been characterized in detail. This study reports (i) the histological features of prostate cancer treated with abiraterone and enzalutamide and inter-pathologist variance in identifying these features, and (ii) the effect of the novel androgen deprivation agents on residual cancer volume.Methods
We reviewed sections of prostatectomies from 37 patients treated with neoadjuvant agents and 22 untreated patients, tabulated the frequency of nine features of cancer (intact cancer glands, isolated cancer cells, poorly formed glands, cribriform architecture, clear spaces, intraductal carcinoma, solid sheets of cancer cells, prominent nucleoli, and previously desc"],"journal":["The Prostate"],"pubmed_title":["A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer."],"pmcid":["PMC4988926"],"funding_grant_id":["P50 CA097186"],"pubmed_authors":["Xia J","Vakar-Lopez F","Montgomery B","Murphy C","True L","Tretiakova M","Gulati R"],"additional_accession":[]},"is_claimable":false,"name":"A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.","description":"Background
Pathologic variables that characterize response of prostate carcinoma to current neoadjuvant therapy have not been characterized in detail. This study reports (i) the histological features of prostate cancer treated with abiraterone and enzalutamide and inter-pathologist variance in identifying these features, and (ii) the effect of the novel androgen deprivation agents on residual cancer volume.Methods
We reviewed sections of prostatectomies from 37 patients treated with neoadjuvant agents and 22 untreated patients, tabulated the frequency of nine features of cancer (intact cancer glands, isolated cancer cells, poorly formed glands, cribriform architecture, clear spaces, intraductal carcinoma, solid sheets of cancer cells, prominent nucleoli, and previously desc","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Oct","modification":"2025-04-04T21:52:14.951Z","creation":"2019-03-27T02:20:54Z"},"accession":"S-EPMC4988926","cross_references":{"pubmed":["27273062"],"doi":["10.1002/pros.23215"]}}